About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Mirikizumab

Company: Eli Lilly and Company
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 16 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

16 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 25, 2026

Trial details

Recruiting NCT NCT04844606

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Not yet reported Eli Lilly and Company 150 participants Est. completion 2030-12 69 sites Stand-alone

Other conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
View official trial listing →
Recruiting NCT NCT05509777

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Not yet reported Eli Lilly and Company 90 participants Est. completion 2028-04 81 sites Stand-alone

Other conditions: Crohn's Disease
View official trial listing →
Recruiting NCT NCT06089590

Ibd CAncer and seRious Infections in France (I-CARE 2)

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives 6000 participants Est. completion 2031-03-01 2 sites

Other conditions: IBD, Ulcerative Colitis, Crohn Disease
View official trial listing →
Recruiting NCT NCT06598943

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Not yet reported Eli Lilly and Company 143 participants Est. completion 2028-09 207 sites Stand-alone

Other conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
View official trial listing →
Recruiting NCT NCT06864403

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Not yet reported University of North Carolina, Chapel Hill 25 participants Est. completion 2027-04 5 sites

Other conditions: Pouchitis, Pouches, Ileoanal, Pouch, Ileal
View official trial listing →
Recruiting NCT NCT06937086

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet reported Eli Lilly and Company 350 participants Est. completion 2028-04 187 sites Mixed

Other conditions: Ulcerative Colitis, Obesity or Overweight
View official trial listing →
Recruiting NCT NCT06937099

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet reported Eli Lilly and Company 290 participants Est. completion 2028-05 183 sites Mixed

Other conditions: Crohn's Disease, Obesity or Overweight
View official trial listing →
Recruiting NCT NCT06997965

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Not yet reported Alimentiv Inc. 60 participants Est. completion 2028-04-01 5 sites

Other conditions: Crohn Disease
View official trial listing →
Recruiting NCT NCT07186101

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Not yet reported Eli Lilly and Company 252 participants Est. completion 2029-03 147 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Recruiting NCT NCT07198113

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

University of North Carolina, Chapel Hill 1100 participants Est. completion 2028-09 4 sites

Other conditions: Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
View official trial listing →
Recruiting NCT NCT07235904

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

Not yet reported University Hospital Schleswig-Holstein 300 participants Est. completion 2028-10 1 site Stand-alone

Other conditions: Ulcerative Colitis (UC)
View official trial listing →
Recruiting NCT NCT07292012

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Not yet reported Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives 75 participants Est. completion 2028-11 6 sites Stand-alone

Other conditions: Crohn Disease (CD)
View official trial listing →
Recruiting NCT NCT07446101

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

Not yet reported Eli Lilly and Company 450 participants Est. completion 2027-02 5 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Recruiting NCT NCT07483073

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Not yet reported Eli Lilly and Company 60 participants Est. completion 2028-03 70 sites Stand-alone

Other conditions: Colitis, Ulcerative, Crohn Disease
View official trial listing →
Recruiting NCT NCT07483099

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Not yet reported Eli Lilly and Company 60 participants Est. completion 2028-03 70 sites Stand-alone

Other conditions: Crohn Disease
View official trial listing →
Recruiting NCT NCT07612267

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

Not yet reported Eli Lilly and Company 14 participants Est. completion 2028-09 20 sites

Other conditions: Lactation, Inflammatory Bowel Disease
View official trial listing →
Completed NCT NCT01947933

A Safety Study of Mirikizumab (LY3074828)

Not yet reported Eli Lilly and Company 45 participants Est. completion 2015-02 2 sites Stand-alone

Other conditions: Psoriasis
View official trial listing →
Completed NCT NCT02568423

A Study of Mirikizumab (LY3074828) in Healthy Participants

Not yet reported Eli Lilly and Company 51 participants Est. completion 2018-10-24 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02589665

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Not yet reported Eli Lilly and Company 249 participants Est. completion 2019-05-07 76 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT02891226

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

Not yet reported Eli Lilly and Company 191 participants Est. completion 2021-02-05 108 sites Stand-alone

Other conditions: Crohn's Disease
View official trial listing →
Completed NCT NCT02899988

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Not yet reported Eli Lilly and Company 205 participants Est. completion 2019-05-08 40 sites Stand-alone

Other conditions: Plaque Psoriasis
View official trial listing →
Completed NCT NCT03053622

A Study of Mirikizumab (LY3074828) Injection in Healthy Participants

Not yet reported Eli Lilly and Company 67 participants Est. completion 2018-04-03 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03188510

A Study of Two Different Formulations of LY3074828 in Healthy Participants

Not yet reported Eli Lilly and Company 54 participants Est. completion 2017-11-27 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03220126

A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants

Not yet reported Eli Lilly and Company 72 participants Est. completion 2018-02-23 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03456713

A Study of LY3074828 in Healthy Participants

Not yet reported Eli Lilly and Company 72 participants Est. completion 2018-08-13 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03482011

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

Not yet reported Eli Lilly and Company 530 participants Est. completion 2020-01-16 69 sites Stand-alone

Other conditions: Psoriasis
View official trial listing →
Completed NCT NCT03518086

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Not yet reported Eli Lilly and Company 1281 participants Est. completion 2024-05-15 502 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Active, not recruiting NCT NCT03519945

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Not yet reported Eli Lilly and Company 1058 participants Est. completion 2027-12 352 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT03524092

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Not yet reported Eli Lilly and Company 1328 participants Est. completion 2025-02-17 385 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT03535194

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Not yet reported Eli Lilly and Company 1484 participants Est. completion 2020-06-03 178 sites Stand-alone

Other conditions: Psoriasis
View official trial listing →
Terminated NCT NCT03556202

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Not yet reported Eli Lilly and Company 1936 participants Est. completion 2022-02-07 229 sites Stand-alone

Other conditions: Psoriasis
View official trial listing →
Completed NCT NCT03662100

A Study of Two Formulations of LY3074828 in Healthy Participants

Not yet reported Eli Lilly and Company 66 participants Est. completion 2019-01-25 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03718884

A Study of Mirikizumab in Participants With Plaque Psoriasis

Not yet reported Eli Lilly and Company 29 participants Est. completion 2019-10-28 3 sites Stand-alone

Other conditions: Psoriasis
View official trial listing →
Completed NCT NCT03748940

Study of LY3074828 in Healthy Participants

Not yet reported Eli Lilly and Company 60 participants Est. completion 2019-06-18 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03886948

A Study of Injections of LY3074828 in Healthy Participants

Not yet reported Eli Lilly and Company 66 participants Est. completion 2019-10-04 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT03926130

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Not yet reported Eli Lilly and Company 1158 participants Est. completion 2023-10-02 580 sites Stand-alone

Other conditions: Crohn's Disease
View official trial listing →
Completed NCT NCT04004611

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

Not yet reported Eli Lilly and Company 26 participants Est. completion 2023-03-15 37 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT04137380

A Study of Mirikizumab in Healthy Chinese Participants

Not yet reported Eli Lilly and Company 60 participants Est. completion 2020-12-11 2 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Active, not recruiting NCT NCT04232553

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Not yet reported Eli Lilly and Company 996 participants Est. completion 2028-03 322 sites Stand-alone

Other conditions: Crohn's Disease
View official trial listing →
Withdrawn NCT NCT04469062

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Not yet reported Eli Lilly and Company Est. completion 2024-06-05 Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT04548219

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

Not yet reported Eli Lilly and Company 60 participants Est. completion 2021-01-11 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT04607733

A Study of Mirikizumab in Healthy Participants

Not yet reported Eli Lilly and Company 240 participants Est. completion 2021-05-17 4 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT05069896

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

Not yet reported Eli Lilly and Company 237 participants Est. completion 2022-06-22 3 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT05515601

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

Not yet reported Eli Lilly and Company 396 participants Est. completion 2023-02-20 6 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT05644353

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Not yet reported Eli Lilly and Company 450 participants Est. completion 2023-05-25 6 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT05767021

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Not yet reported Eli Lilly and Company 172 participants Est. completion 2026-04-27 120 sites Stand-alone

Other conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
View official trial listing →
Completed NCT NCT05784246

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Not yet reported Eli Lilly and Company 63 participants Est. completion 2026-05-01 34 sites Stand-alone

Other conditions: Ulcerative Colitis
View official trial listing →
Active, not recruiting NCT NCT06249555

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Alimentiv Inc. 300 participants Est. completion 2026-12 24 sites

Other conditions: Crohn's Disease
View official trial listing →
Completed NCT NCT06475729

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

Not yet reported Eli Lilly and Company 498 participants Est. completion 2024-12-27 6 sites Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT06626165

Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa

Not yet reported Showa Inan General Hospital 100 participants Est. completion 2025-09-30 1 site

Other conditions: Ulcerative Colitis
View official trial listing →
Terminated NCT NCT06696014

Mirikizumab Real World Protocol

University of North Carolina, Chapel Hill 6 participants Est. completion 2026-07-08 9 sites

Other conditions: Ulcerative Colitis
View official trial listing →
Not yet recruiting NCT NCT07059130

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

Not yet reported Rubix LS 150 participants Est. completion 2026-02-28 1 site Stand-alone

Other conditions: Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
View official trial listing →
Not yet recruiting NCT NCT07659353

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease

Not yet reported University Hospital Schleswig-Holstein 320 participants Est. completion 2029-03-31 1 site Stand-alone

Other conditions: Chrohn's Disease
View official trial listing →
Enrolling by invitation NCT NCT07686757

INSIGHT-IBD Pragmatic Study

Not yet reported Specialty Networks Research. 400 participants Est. completion 2028-06 10 sites

Other conditions: Ulcerative Colitis (UC), Crohn Disease (CD)
View official trial listing →
Completed NCT NCT07695636

Effectiveness and Safety of Mirikizumab in Patients With Moderate-to-severe Ulcerative Colitis: a Real-life Retrospective Multicenter Study

IRCCS San Raffaele 282 participants Est. completion 2026-01-01 1 site

Other conditions: Ulcerative Colitis (UC)
View official trial listing →
Not yet recruiting NCT NCT07782021

MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease

Not yet reported Icahn School of Medicine at Mount Sinai 50 participants Est. completion 2029-07 2 sites Stand-alone

Other conditions: Crohn's Disease, Perianal Fistula
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT06937099

Also known as: Mirikizumab, Omvoh, LY3074828

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.